What is the 13F Pro Quality Score for MREO?

13F Pro ranks Mereo BioPharma Group plc (MREO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MREO's current score at https://13fpro.ai/research/MREO (free sign-up required for the full ranking).

Which hedge funds own the most MREO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MREO include Rubric Capital Management, EcoR1 Capital,, 683 Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MREO as soon as new 13F filings post.

Where does 13F Pro source MREO data?

All Mereo BioPharma Group plc fundamentals and ownership data come directly from SEC EDGAR. Mereo BioPharma Group plc files with the SEC under CIK 1719714. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MREO in?

Mereo BioPharma Group plc (MREO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MREO research updated on 13F Pro?

MREO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Mereo BioPharma Group plc(MREO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1719714 MREO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $36.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MREO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Mereo BioPharma Group plc (MREO), a Healthcare sector company. MREO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $36.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Mereo BioPharma Group plc reports net income of $-6.7M, free cash flow of $-4.3M. Top institutional holders of MREO by reported 13-F value include Rubric Capital Management, EcoR1 Capital,, 683 Capital Management,, based on the most recent SEC filings. MREO trades on the Nasdaq exchange and files with the SEC under CIK 1719714. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MREO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mereo BioPharma Group plc directly from SEC EDGAR.

Net Income

Q1 2026

$-6.7M

Free Cash Flow

Q1 2026

$-4.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$500.0KFY 2025

FY22 $0.00FY23 $10.0MFY24 $0.00FY25 $500.0K

Net Income

+3.2% YoY

$-41.9MFY 2025

FY22 $-42.2MFY23 $-29.5MFY24 $-43.3MFY25 $-41.9M

Operating Income

+15.3% YoY

$-40.1MFY 2025

FY22 $-54.4MFY23 $-28.4MFY24 $-47.4MFY25 $-40.1M

EPS (Diluted)

+16.7% YoY

$-0.05FY 2025

FY22 $-0.07FY23 $-0.04FY24 $-0.06FY25 $-0.05

Total Assets

-39.9% YoY

$45.9MFY 2025

FY22 $77.4MFY23 $66.5MFY24 $76.4MFY25 $45.9M

Op. Cash Flow

+5.7% YoY

$-31.0MFY 2025

FY22 $-48.8MFY23 $-21.1MFY24 $-32.8MFY25 $-31.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$500.0K	$0.00 -100.0%	$10.0M	$0.00
Net Income	$-41.9M +3.2%	$-43.3M -46.8%	$-29.5M +30.2%	$-42.2M
Operating Income	$-40.1M +15.3%	$-47.4M -66.7%	$-28.4M +47.8%	$-54.4M
EPS (Diluted)	$-0.05 +16.7%	$-0.06 -50.0%	$-0.04 +42.9%	$-0.07
Total Assets	$45.9M -39.9%	$76.4M +14.9%	$66.5M -14.1%	$77.4M
Operating Cash Flow	$-31.0M +5.7%	$-32.8M -55.4%	$-21.1M +56.7%	$-48.8M

AI Insight: MREO Financial Trends

Pre-revenue biotech burning through equity at accelerating pace, with cash consumption remaining stubbornly high despite modest operational efficiency gains.

• Operating income loss narrowed from $15M in Q4 2024 to $8M in Q4 2025, showing operational discipline.

• Equity eroded 57% from $79M in Q2 2024 to $34M in Q1 2026, signaling acute capital depletion.

• Operating cash burn remains elevated at $4M–$9M per quarter; Q1 2026 showed $4M outflow despite low operating income.

⚠ Equity runway: at current burn rates, existing balance sheet supports only 8–10 additional quarters without fundraising.

⚠ No revenue generation across entire 9-quarter window; clinical/commercial inflection remains unproven.

AI Insight: MREO Ratio Trends

Mereo BioPharma remains deeply unprofitable with deteriorating return metrics across all quarters; no path to profitability visible in trailing data.

• ROE deteriorated to -78.9% in Q1 2026 from -46.2% in Q4 2024, signaling worsening shareholder value destruction.

• ROA declined to -66.2% in Q1 2026 from -36.9% in Q4 2024, indicating asset base is generating substantial losses.

• ROIC contracted to -86.0% in Q3 2025 from -51.7% in Q3 2024, showing capital is failing to generate returns.

⚠ TTM ROE of -104.9% and ROA of -87.9% signal sustained cash burn; monitor cash runway and financing needs.

⚠ Volatility in quarterly ROIC (-51.7% to -86.0%) suggests operational instability or material one-off charges.

Get alerted when MREO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Mereo BioPharma Group plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MREO

Rubric Capital Management LP
$5.1M15,307,347 sh
EcoR1 Capital, LLC
$4.4M13,368,855 sh
683 Capital Management, LLC
$4.0M12,000,000 sh
BANK OF AMERICA CORP /DE/
$2.7M8,195,287 sh
Defilade Capital Management, L.P.
$2.5M7,558,756 sh
Newtyn Management, LLC
$2.3M7,079,056 sh
MILLENNIUM MANAGEMENT LLC
$1.2M3,559,103 sh
Tejara Capital Ltd
$672.4K2,037,520 sh
UBS Group AG
$491.7K1,490,128 sh
Wealthspire Advisors, LLC
$262.7K796,036 sh

Fund	Value	Shares
Rubric Capital Management LP	$5.1M	15,307,347
EcoR1 Capital, LLC	$4.4M	13,368,855
683 Capital Management, LLC	$4.0M	12,000,000
BANK OF AMERICA CORP /DE/	$2.7M	8,195,287
Defilade Capital Management, L.P.	$2.5M	7,558,756
Newtyn Management, LLC	$2.3M	7,079,056
MILLENNIUM MANAGEMENT LLC	$1.2M	3,559,103
Tejara Capital Ltd	$672.4K	2,037,520
UBS Group AG	$491.7K	1,490,128
Wealthspire Advisors, LLC	$262.7K	796,036

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MREO on your watchlist

Track score changes the day Mereo BioPharma Group plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MREO a good stock to buy?

13F Pro's AI-powered analysis of Mereo BioPharma Group plc (MREO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MREO are available on the MREO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MREO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MREO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mereo BioPharma Group plc's investment landscape.